UBS Group
INDV icon

UBS Group’s Indivior Pharmaceuticals INDV Stock Holding History

UBS Group’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$47.6M Sell
1,160,618
-1,031,646
-47% -$37.4M 0.01% 1786
2026
Q1 		$66.8M Buy
2,192,264
+1,403,698
+178% +$46.4M 0.01% 1362
2025
Q4 		$28.3M Sell
788,566
-5,197
-0.7% -$159K ﹤0.01% 2238
2025
Q3 		$19.1M Sell
793,763
-1,594,227
-67% -$33.4M ﹤0.01% 2615
2025
Q2 		$35.2M Sell
2,387,990
-1,139,289
-32% -$13.3M 0.01% 1835
2025
Q1 		$33.6M Buy
3,527,279
+2,694,468
+324% +$28.3M 0.01% 1846
2024
Q4 		$10.4M Sell
832,811
-9,320
-1% -$95.9K ﹤0.01% 3002
2024
Q3 		$8.21M Sell
842,131
-957,453
-53% -$11.2M ﹤0.01% 2557
2024
Q2 		$29M Buy
1,799,584
+321,355
+22% +$5.8M 0.01% 1399
2024
Q1 		$31.7M Buy
1,478,229
+652,099
+79% +$12.2M 0.01% 1357
2023
Q4 		$12.6M Buy
826,130
+345,556
+72% +$6.14M ﹤0.01% 1911
2023
Q3 		$11.1M Sell
480,574
-345,738
-42% -$7.88M ﹤0.01% 1911
2023
Q2 		$19.7M Buy
+826,312
New +$18.9M 0.01% 1465

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group's INDV Position: Q2 2026 in Review

UBS Group reduced its Indivior Pharmaceuticals (INDV) stake by 47% in Q2 2026, selling an estimated $37.4M and leaving 1,160,618 shares worth $47.6M. The position accounts for 0.01% of the portfolio, ranked #1786.

UBS Group first reported a position in INDV in Q2 2023 and has held it in 13 quarters since. The position peaked at $66.8M in Q1 2026. 336 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • UBS Group held 1,160,618 shares of Indivior Pharmaceuticals worth $47.6M as of Q2 2026.
  • UBS Group sold 1,031,646 Indivior Pharmaceuticals shares in Q2 2026, an estimated $37.4M.
  • Indivior Pharmaceuticals made up 0.01% of UBS Group's portfolio in Q2 2026, its #1786 holding.
  • UBS Group first reported a position in Indivior Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • UBS Group's Indivior Pharmaceuticals position peaked at $66.8M in Q1 2026.
  • 336 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.